Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has finalized an agreement to acquire Novitium Pharma for $163.5 million, comprising $89.5 million in cash and $74 million in equity. The acquisition aims to enhance ANI's generics business and R&D capabilities, with a focus on niche opportunities. Expected to close in H2 2021, pending regulatory approvals, the deal is projected to be immediately accretive to adjusted EBITDA, contributing approximately $15 million to adjusted EBITDA within the first year. The transaction is supported by new financing, including a $300 million Term Loan B.
ANI Pharmaceuticals announced the grant of non-qualified inducement stock options totaling 60,764 shares to two executives, Ori Gutwerg and Christopher Mutz, effective February 15, 2021. These options were provided as employment inducements in line with Nasdaq rules and will vest annually over four years. The options have an exercise price of $31.49 per share, matching the stock's closing price on February 12, 2021. They also feature acceleration clauses in case of a change in control or certain employment terminations.
ANI Pharmaceuticals announced the hiring of three key executives: Christopher K. Mutz as Chief Commercial Officer and Head of Rare Diseases, Ori Gutwerg as Senior Vice President of Generics, and Davinder Singh as General Manager of Canadian Operations. These additions are set to enhance ANI's leadership team to accelerate growth across its business units. Additionally, Robert Schrepfer, Senior VP of Business Development, will leave the company next month for another opportunity.
ANI Pharmaceuticals (NASDAQ: ANIP) will announce its fourth quarter and full year 2020 financial results on March 9, 2021. Nikhil Lalwani, President and CEO, along with Stephen P. Carey, CFO, will lead a conference call at 8:30 a.m. ET to discuss the results. Interested parties can join the call via a toll-free number or listen to a live webcast on the company’s website. A replay of the call will be available shortly after its conclusion, accessible for one week.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has launched Prazosin HCl Capsules USP in 1mg and 2mg, following FDA approval of its prior approval supplement application. The U.S. market for these strengths is approximately $46.2 million, as per IQVIA/IMS Health. This marks ANI's fourteenth re-commercialization of a discontinued ANDA product, showcasing its commitment to maximizing product portfolio value. Prazosin is used to treat hypertension, thereby reducing cardiovascular event risks, including strokes and heart attacks.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has received FDA approval for Aminocaproic Acid Tablets USP, 500mg, marking its seventh generic product launch in 2020. The U.S. market for this product is valued at approximately $12.7 million, highlighting its significance in enhancing hemostasis during bleeding situations. This launch is part of ANI's strategy to accelerate its product introductions, stemming from its acquisition of a generic pipeline from Amerigen Pharmaceuticals. The company anticipates more product launches in the future, focusing on realizing its portfolio potential.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) reported Q3 2020 net revenues of $53.0 million, a rise from $51.3 million in Q3 2019, driven largely by a 18.8% increase in generic pharmaceutical product sales. The company posted a GAAP net income of $0.4 million and diluted EPS of $0.04. However, revenues from branded products fell 25.3%. Operating expenses rose to $50.2 million, resulting in an adjusted non-GAAP diluted EPS of $0.97, down from $1.23 year-over-year. ANI remains focused on the upcoming launch of Cortrophin Gel and CEO Nikhil Lalwani's strategy for growth.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced it will release its third quarter 2020 financial results on November 5, 2020, before U.S. market opening. The conference call, hosted by CEO Nikhil Lalwani and CFO Stephen P. Carey, will be held at 10:30 a.m. ET. Investors can join by dialing (866) 776-8875 or via webcast at the company's website. A replay will be available for one week after the call.
ANI focuses on developing high-quality branded and generic pharmaceuticals in areas including controlled substances and oncolytics.
ANI Pharmaceuticals announced the acquisition of Fluconazole Tablets USP from a private company for $3.0 million. The product's current annual U.S. market is valued at approximately $40 million, indicating significant market opportunity. Interim President and CEO Patrick Walsh expressed enthusiasm for integrating this product into ANI's portfolio, which is expected to enhance margins and competitive positioning. Fluconazole Tablets are used primarily for treating vaginal and esophageal candidiasis, among other conditions.
ANI Pharmaceuticals announced the launch of Mexiletine Hydrochloride Capsules USP, available in 150mg, 200mg, and 250mg dosages, targeting a $16 million U.S. market. This marks ANI's sixth generic product launch in 2020 and the first from its Oakville, Canada site, which was acquired in August 2018. Mexiletine is indicated for treating life-threatening ventricular arrhythmias. The company's Interim President and CEO, Patrick Walsh, emphasized the milestone's importance for future product development.